The bolger conference on PDE-5 inhibition and HIV Risk: Implications for health policy and prevention

Raymond C. Rosen, Joseph A. Catania, Anke A. Ehrhardt, Arthur L. Burnett, Tom F. Lue, Kevin Mckenna, Julia R. Heiman, Sandy Schwarcz, David G. Ostrow, Sabina Hirshfield, David W. Purcell, William A. Fisher, Ron Stall, Perry N. Halkitis, David M. Latini, Jonathan Elford, Edward O. Laumann, Freya L. Sonenstein, David J. Greenblatt, Robert A. KlonerJay Lee, David Malebranche, Erick Janssen, Rafael Diaz, Jeffrey D. Klausner, Arthur L. Caplan, Graham Jackson, Ridwan Shabsigh, Jag H. Khalsa, David M. Stoff

Research output: Contribution to journalArticle

Abstract

Introduction. Recent reports have linked the use of phosphodiesterase type 5 (PDE-5) inhibitors with increased rates of high-risk sexual behavior and HIV transmission in some individuals. Aim. A National Institute of Mental Health (NIMH)-funded, multidisciplinary conference was convened to evaluate scientific research, clinical and ethical considerations, and public policy implications of this topic. Main Outcome Measures. Published and unpublished findings on effects of PDE-5 inhibitors on sexual behavior; published guidelines and management recommendations. Methods. Leading investigators in relevant disciplines (e.g., public health, epidemiology, medical ethics, urology, psychology) participated in a 2-day meeting, including representatives of government, scientific, and regulatory agencies (the Centers for Disease Control, Food and Drug Administration, NIMH, and the National Institute on Drug Abuse). Panelists provided critical reviews of substantive areas of research, followed by question and answer sessions on each topic. On the second day, working groups were convened to identify critical gaps and priorities in three major areas: (i) research and evaluation needs; (ii) prevention strategies and clinical management issues; and (iii) policy and prevention implications. Results. Research needs and priorities were categorized into four specific areas: (i) basic and clinical/laboratory research; (ii) epidemiology and risk factors; (iii) social-behavioral processes and interventions; and (iv) prevention/policy and educational needs. Identified gaps in the available data include populations at risk (e.g., risk among heterosexuals, risk profiles among subpopulations of men who have sex with men) and the specific role of PDE-5 inhibitors in HIV seroconversion. Specific areas of emphasis were the need for safer sex counseling, comprehensive sexually transmitted infection (STI) screening and follow-up when indicated, avoidance of potentially dangerous drug interactions, and potential benefits of testosterone replacement for HIV-positive men with decreased androgen and other symptoms of hypogonadism. Conclusions. A conference was convened on the topic of PDE-5 inhibition and HIV risk. This "white paper" summarizes the findings of the conference and recommendations for future research.

Original languageEnglish (US)
Pages (from-to)960-973
Number of pages14
JournalJournal of Sexual Medicine
Volume3
Issue number6
DOIs
StatePublished - Nov 2006

Fingerprint

Type 5 Cyclic Nucleotide Phosphodiesterases
Health Policy
Phosphodiesterase 5 Inhibitors
HIV
National Institute of Mental Health (U.S.)
Research
Sexual Behavior
Sex Counseling
Epidemiology
National Institute on Drug Abuse (U.S.)
HIV Seropositivity
Safe Sex
Medical Ethics
Hypogonadism
Heterosexuality
Urology
United States Food and Drug Administration
Public Policy
Centers for Disease Control and Prevention (U.S.)
Sexually Transmitted Diseases

Keywords

  • HIV/AIDS
  • Phosphodiesterase type 5 (PDE-5) inhibitor
  • Sexual risk behavior

ASJC Scopus subject areas

  • Urology
  • Obstetrics and Gynecology

Cite this

Rosen, R. C., Catania, J. A., Ehrhardt, A. A., Burnett, A. L., Lue, T. F., Mckenna, K., ... Stoff, D. M. (2006). The bolger conference on PDE-5 inhibition and HIV Risk: Implications for health policy and prevention. Journal of Sexual Medicine, 3(6), 960-973. https://doi.org/10.1111/j.1743-6109.2006.00323.x

The bolger conference on PDE-5 inhibition and HIV Risk : Implications for health policy and prevention. / Rosen, Raymond C.; Catania, Joseph A.; Ehrhardt, Anke A.; Burnett, Arthur L.; Lue, Tom F.; Mckenna, Kevin; Heiman, Julia R.; Schwarcz, Sandy; Ostrow, David G.; Hirshfield, Sabina; Purcell, David W.; Fisher, William A.; Stall, Ron; Halkitis, Perry N.; Latini, David M.; Elford, Jonathan; Laumann, Edward O.; Sonenstein, Freya L.; Greenblatt, David J.; Kloner, Robert A.; Lee, Jay; Malebranche, David; Janssen, Erick; Diaz, Rafael; Klausner, Jeffrey D.; Caplan, Arthur L.; Jackson, Graham; Shabsigh, Ridwan; Khalsa, Jag H.; Stoff, David M.

In: Journal of Sexual Medicine, Vol. 3, No. 6, 11.2006, p. 960-973.

Research output: Contribution to journalArticle

Rosen, RC, Catania, JA, Ehrhardt, AA, Burnett, AL, Lue, TF, Mckenna, K, Heiman, JR, Schwarcz, S, Ostrow, DG, Hirshfield, S, Purcell, DW, Fisher, WA, Stall, R, Halkitis, PN, Latini, DM, Elford, J, Laumann, EO, Sonenstein, FL, Greenblatt, DJ, Kloner, RA, Lee, J, Malebranche, D, Janssen, E, Diaz, R, Klausner, JD, Caplan, AL, Jackson, G, Shabsigh, R, Khalsa, JH & Stoff, DM 2006, 'The bolger conference on PDE-5 inhibition and HIV Risk: Implications for health policy and prevention', Journal of Sexual Medicine, vol. 3, no. 6, pp. 960-973. https://doi.org/10.1111/j.1743-6109.2006.00323.x
Rosen, Raymond C. ; Catania, Joseph A. ; Ehrhardt, Anke A. ; Burnett, Arthur L. ; Lue, Tom F. ; Mckenna, Kevin ; Heiman, Julia R. ; Schwarcz, Sandy ; Ostrow, David G. ; Hirshfield, Sabina ; Purcell, David W. ; Fisher, William A. ; Stall, Ron ; Halkitis, Perry N. ; Latini, David M. ; Elford, Jonathan ; Laumann, Edward O. ; Sonenstein, Freya L. ; Greenblatt, David J. ; Kloner, Robert A. ; Lee, Jay ; Malebranche, David ; Janssen, Erick ; Diaz, Rafael ; Klausner, Jeffrey D. ; Caplan, Arthur L. ; Jackson, Graham ; Shabsigh, Ridwan ; Khalsa, Jag H. ; Stoff, David M. / The bolger conference on PDE-5 inhibition and HIV Risk : Implications for health policy and prevention. In: Journal of Sexual Medicine. 2006 ; Vol. 3, No. 6. pp. 960-973.
@article{a1821525b3534734980bd18d227057f8,
title = "The bolger conference on PDE-5 inhibition and HIV Risk: Implications for health policy and prevention",
abstract = "Introduction. Recent reports have linked the use of phosphodiesterase type 5 (PDE-5) inhibitors with increased rates of high-risk sexual behavior and HIV transmission in some individuals. Aim. A National Institute of Mental Health (NIMH)-funded, multidisciplinary conference was convened to evaluate scientific research, clinical and ethical considerations, and public policy implications of this topic. Main Outcome Measures. Published and unpublished findings on effects of PDE-5 inhibitors on sexual behavior; published guidelines and management recommendations. Methods. Leading investigators in relevant disciplines (e.g., public health, epidemiology, medical ethics, urology, psychology) participated in a 2-day meeting, including representatives of government, scientific, and regulatory agencies (the Centers for Disease Control, Food and Drug Administration, NIMH, and the National Institute on Drug Abuse). Panelists provided critical reviews of substantive areas of research, followed by question and answer sessions on each topic. On the second day, working groups were convened to identify critical gaps and priorities in three major areas: (i) research and evaluation needs; (ii) prevention strategies and clinical management issues; and (iii) policy and prevention implications. Results. Research needs and priorities were categorized into four specific areas: (i) basic and clinical/laboratory research; (ii) epidemiology and risk factors; (iii) social-behavioral processes and interventions; and (iv) prevention/policy and educational needs. Identified gaps in the available data include populations at risk (e.g., risk among heterosexuals, risk profiles among subpopulations of men who have sex with men) and the specific role of PDE-5 inhibitors in HIV seroconversion. Specific areas of emphasis were the need for safer sex counseling, comprehensive sexually transmitted infection (STI) screening and follow-up when indicated, avoidance of potentially dangerous drug interactions, and potential benefits of testosterone replacement for HIV-positive men with decreased androgen and other symptoms of hypogonadism. Conclusions. A conference was convened on the topic of PDE-5 inhibition and HIV risk. This {"}white paper{"} summarizes the findings of the conference and recommendations for future research.",
keywords = "HIV/AIDS, Phosphodiesterase type 5 (PDE-5) inhibitor, Sexual risk behavior",
author = "Rosen, {Raymond C.} and Catania, {Joseph A.} and Ehrhardt, {Anke A.} and Burnett, {Arthur L.} and Lue, {Tom F.} and Kevin Mckenna and Heiman, {Julia R.} and Sandy Schwarcz and Ostrow, {David G.} and Sabina Hirshfield and Purcell, {David W.} and Fisher, {William A.} and Ron Stall and Halkitis, {Perry N.} and Latini, {David M.} and Jonathan Elford and Laumann, {Edward O.} and Sonenstein, {Freya L.} and Greenblatt, {David J.} and Kloner, {Robert A.} and Jay Lee and David Malebranche and Erick Janssen and Rafael Diaz and Klausner, {Jeffrey D.} and Caplan, {Arthur L.} and Graham Jackson and Ridwan Shabsigh and Khalsa, {Jag H.} and Stoff, {David M.}",
year = "2006",
month = "11",
doi = "10.1111/j.1743-6109.2006.00323.x",
language = "English (US)",
volume = "3",
pages = "960--973",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - The bolger conference on PDE-5 inhibition and HIV Risk

T2 - Implications for health policy and prevention

AU - Rosen, Raymond C.

AU - Catania, Joseph A.

AU - Ehrhardt, Anke A.

AU - Burnett, Arthur L.

AU - Lue, Tom F.

AU - Mckenna, Kevin

AU - Heiman, Julia R.

AU - Schwarcz, Sandy

AU - Ostrow, David G.

AU - Hirshfield, Sabina

AU - Purcell, David W.

AU - Fisher, William A.

AU - Stall, Ron

AU - Halkitis, Perry N.

AU - Latini, David M.

AU - Elford, Jonathan

AU - Laumann, Edward O.

AU - Sonenstein, Freya L.

AU - Greenblatt, David J.

AU - Kloner, Robert A.

AU - Lee, Jay

AU - Malebranche, David

AU - Janssen, Erick

AU - Diaz, Rafael

AU - Klausner, Jeffrey D.

AU - Caplan, Arthur L.

AU - Jackson, Graham

AU - Shabsigh, Ridwan

AU - Khalsa, Jag H.

AU - Stoff, David M.

PY - 2006/11

Y1 - 2006/11

N2 - Introduction. Recent reports have linked the use of phosphodiesterase type 5 (PDE-5) inhibitors with increased rates of high-risk sexual behavior and HIV transmission in some individuals. Aim. A National Institute of Mental Health (NIMH)-funded, multidisciplinary conference was convened to evaluate scientific research, clinical and ethical considerations, and public policy implications of this topic. Main Outcome Measures. Published and unpublished findings on effects of PDE-5 inhibitors on sexual behavior; published guidelines and management recommendations. Methods. Leading investigators in relevant disciplines (e.g., public health, epidemiology, medical ethics, urology, psychology) participated in a 2-day meeting, including representatives of government, scientific, and regulatory agencies (the Centers for Disease Control, Food and Drug Administration, NIMH, and the National Institute on Drug Abuse). Panelists provided critical reviews of substantive areas of research, followed by question and answer sessions on each topic. On the second day, working groups were convened to identify critical gaps and priorities in three major areas: (i) research and evaluation needs; (ii) prevention strategies and clinical management issues; and (iii) policy and prevention implications. Results. Research needs and priorities were categorized into four specific areas: (i) basic and clinical/laboratory research; (ii) epidemiology and risk factors; (iii) social-behavioral processes and interventions; and (iv) prevention/policy and educational needs. Identified gaps in the available data include populations at risk (e.g., risk among heterosexuals, risk profiles among subpopulations of men who have sex with men) and the specific role of PDE-5 inhibitors in HIV seroconversion. Specific areas of emphasis were the need for safer sex counseling, comprehensive sexually transmitted infection (STI) screening and follow-up when indicated, avoidance of potentially dangerous drug interactions, and potential benefits of testosterone replacement for HIV-positive men with decreased androgen and other symptoms of hypogonadism. Conclusions. A conference was convened on the topic of PDE-5 inhibition and HIV risk. This "white paper" summarizes the findings of the conference and recommendations for future research.

AB - Introduction. Recent reports have linked the use of phosphodiesterase type 5 (PDE-5) inhibitors with increased rates of high-risk sexual behavior and HIV transmission in some individuals. Aim. A National Institute of Mental Health (NIMH)-funded, multidisciplinary conference was convened to evaluate scientific research, clinical and ethical considerations, and public policy implications of this topic. Main Outcome Measures. Published and unpublished findings on effects of PDE-5 inhibitors on sexual behavior; published guidelines and management recommendations. Methods. Leading investigators in relevant disciplines (e.g., public health, epidemiology, medical ethics, urology, psychology) participated in a 2-day meeting, including representatives of government, scientific, and regulatory agencies (the Centers for Disease Control, Food and Drug Administration, NIMH, and the National Institute on Drug Abuse). Panelists provided critical reviews of substantive areas of research, followed by question and answer sessions on each topic. On the second day, working groups were convened to identify critical gaps and priorities in three major areas: (i) research and evaluation needs; (ii) prevention strategies and clinical management issues; and (iii) policy and prevention implications. Results. Research needs and priorities were categorized into four specific areas: (i) basic and clinical/laboratory research; (ii) epidemiology and risk factors; (iii) social-behavioral processes and interventions; and (iv) prevention/policy and educational needs. Identified gaps in the available data include populations at risk (e.g., risk among heterosexuals, risk profiles among subpopulations of men who have sex with men) and the specific role of PDE-5 inhibitors in HIV seroconversion. Specific areas of emphasis were the need for safer sex counseling, comprehensive sexually transmitted infection (STI) screening and follow-up when indicated, avoidance of potentially dangerous drug interactions, and potential benefits of testosterone replacement for HIV-positive men with decreased androgen and other symptoms of hypogonadism. Conclusions. A conference was convened on the topic of PDE-5 inhibition and HIV risk. This "white paper" summarizes the findings of the conference and recommendations for future research.

KW - HIV/AIDS

KW - Phosphodiesterase type 5 (PDE-5) inhibitor

KW - Sexual risk behavior

UR - http://www.scopus.com/inward/record.url?scp=33750448966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750448966&partnerID=8YFLogxK

U2 - 10.1111/j.1743-6109.2006.00323.x

DO - 10.1111/j.1743-6109.2006.00323.x

M3 - Article

C2 - 17100928

AN - SCOPUS:33750448966

VL - 3

SP - 960

EP - 973

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 6

ER -